Adjuvant Acupuncture for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD/NAFLD): Meta-Analysis Points to Modest Signals on Liver Markers

Metabolic dysfunction-associated steatotic liver disease (MASLD — formerly NAFLD) is the most prevalent form of chronic liver disease worldwide, affecting 25% to 30% of adults and up to 70% of patients with type 2 diabetes and obesity. Standard treatment hinges on sustained weight loss and control of the components of metabolic syndrome. Specific pharmacotherapy is limited — resmetirom was recently approved in the U.S. for MASH/NASH — and GLP-1 agonists (semaglutide) are gaining ground due to effects on weight and the liver. Acupuncture has been investigated as a metabolic-hepatic adjunct.

What the Literature Shows

Meta-analyses suggest modest reductions in liver markers (ALT, AST) and in anthropometric measures (BMI, abdominal circumference) in the adjuvant acupuncture group compared with control. There are also signs of improvement in the lipid profile (total cholesterol, LDL, triglycerides). The effects are, however, modest in magnitude — smaller than those obtained with sustained weight loss of 7–10% or with GLP-1 agonists. Evidence on objective reduction of steatosis by elastography or of fibrosis is limited and inconclusive.

Mechanistic Plausibility

Translational studies suggest an effect of electroacupuncture on the metabolic axis via modulation of incretins (GLP-1), regulation of hepatic vagal tone, reduction of systemic inflammatory markers (TNF-α, IL-6), and attenuation of oxidative stress. There are also data on modulation of the intestinal microbiota and intestinal permeability, pathways relevant to the pathogenesis of MASLD via the gut-liver axis.

Important Limitations

The literature is dominated by Asian studies, with moderate sample sizes and short follow-ups (generally < 6 months). The observed effects are modest in magnitude and do not replace the pillar of treatment — sustained weight loss and structured physical activity. Histologic outcomes (NASH, fibrosis) are rarely evaluated, and data on progression to cirrhosis or hepatocellular carcinoma are nonexistent.